Home > Securing wider EU commitment to the elimination of HCV.

Wedemeyer, Heiner and Tergast, Tammo L and Lazarus, Jeffrey V and Razavi, Homie and Bakoyannis, Kostas and Baptista-Leite, Ricardo and Bartoli, Marco and Bruggmann, Philip and Buşoi, Cristian-Silviu and Buti, Maria and Carballo, Manuel and Castera, Laurent and Colombo, Massimo and Coutinho, Rodrigo Sousa and Dadon, Yuval and Esmat, Gamal and Esteban, Rafael and Colom Farran, Joan and Gillyon-Powell, Mark and Goldberg, David and Hutchinson, Sharon and Janssen, Harry L A and Kalamitsis, George and Kondili, Loreta A and Lambert, John S and Marinho, Rui Tato and Maticic, Mojca and Patricello, Aldo and Peck-Radosavljevic, Markus and Pol, Stanislas and Poljak, Mario and Pop, Cora and Sokol, Tomislov and Sypsa, Vana and Tözün, Nurdan and Younossi, Zobair and Aghemo, Alessio and Papatheodoridis, George V and Hatzakis, Angelos (2023) Securing wider EU commitment to the elimination of HCV. Liver International, 43, (2), pp. 276-291. doi: 10.1111/liv.15446.

External website: https://onlinelibrary.wiley.com/doi/10.1111/liv.15...

In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programs - from the municipality level to the EU level - were launched, resulting in an overall decrease of viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the 3rd EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and report the 'Call-to-Action' statement supported by all the major relevant European associations in the field.

Repository Staff Only: item control page